Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 3/2017

01-03-2017 | Short Communication

A Randomized, Single-Blind Trial of Clobetasol Propionate 0.05% Cream Under Silicone Dressing Occlusion Versus Intra-Lesional Triamcinolone for Treatment of Keloid

Authors: Norazirah Md Nor, Rasimah Ismail, Adawiyah Jamil, Shamsul Azhar Shah, Farah Hani Imran

Published in: Clinical Drug Investigation | Issue 3/2017

Login to get access

Abstract

Background and Objective

Keloid is conventionally treated with intra-lesional (IL) triamcinolone, which is highly operator dependent and has its own adverse effects. Topical steroid and silicone dressings are a patient friendly and non-invasive treatment alternative. We therefore sought to determine the efficacy and safety of topical clobetasol propionate (Dermovate®) 0.05% cream under occlusion with Mepiform® silicone dressing compared to IL triamcinolone in the treatment of keloid.

Methods

This was a prospective, randomised, observer-blinded study. Two keloids on the same site were randomly assigned to receive either daily topical clobetasol propionate 0.05% cream under occlusion with silicone dressing (Scar 1) or monthly IL triamcinolone injection (Scar 2). Efficacy was assessed using patient and observer scar assessment scale (POSAS) at 4-weekly intervals up to 12 weeks. Dimension of keloid and adverse effects were also assessed.

Results

A total of 34 scars from 17 patients completed the study. There was significant improvement of POSAS at 12 weeks compared to baseline within each treatment group. However, there was no statistically significant difference in POSAS at 12 weeks between the two treatments. Keloid dimensions showed a similar trend of improvement by week 12 with either treatment (p = 0.002 in Scar 1, p = 0.005 for Scar 2). However, there was no significant difference between the treatment. In the IL triamcinolone group, all patients reported pain and 70.6% observed necrotic skin reaction. There was a significantly higher rate of adverse effects such as erythema (41.2 vs. 17.6%), hypopigmentation (35.3 vs. 23.5%), telangiectasia (41.2 vs. 17.6%) and skin atrophy (23.5 vs. 5.9%) documented in the IL triamcinolone group when compared to clobetasol propionate 0.05% cream under occlusion with silicone dressing.

Conclusion

Clobetasol propionate 0.05% cream under occlusion with silicone dressing is equally effective and has fewer adverse effects compared to IL triamcinolone. Hence, it may be used as an alternative treatment for keloid particularly in patients with low pain threshold, needle phobia and those who prefers home-based treatment.
Literature
1.
Al-Attar A, Mess S, Thomassen JM, Kauffman CL, Davison SP. Keloid pathogenesis and treatment. Plast Reconstr Surg. 2006;117(1):286–300.CrossRefPubMed
2.
Nast A, Eming S, Fluhr J, et al. German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids). J Dtsch Dermatol Ges. 2012;10(10):747–62.PubMed
3.
Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol. 2002;l46(2 Suppl Understanding):S63–97.
4.
Kim S, Choi TH, Liu W, Ogawa R, Suh JS, Mustoe TA. Update on scar management: guidelines for treating Asian patients. Plast Reconstr Surg. 2013;132(6):1580–9.CrossRefPubMed
5.
Meaume S, Le Pillouer-Prost A, Richert B, Roseeuw D, Vadoud J. Management of scars: updated practical guidelines and use of silicones. Eur J Dermatol. 2014;24(4):435–43.PubMed
6.
Monstrey S, Middelkoop E, Vranckx JJ, Bassetto F, Ziegler UE, et al. Updated scar management practical guidelines: non-invasive and invasive measures. J Plast Reconstr Aesthet Surg. 2014;67(8):1017–25.CrossRefPubMed
7.
Berman B, Perez OA, Konda S, Kohut BE, Viera MH, et al. A review of the biologic effects, clinical efficacy, and safety of silicone elastomer sheeting for hypertrophic and keloid scar treatment and management. Dermatol Surg. 2007;33(11):1291–302.PubMed
8.
Chang CC, Kuo YF, Chiu HC, Lee JL, Wong TW, Jee SH. Hydration, not silicone, modulates the effects of keratinocytes on fibroblasts. J Surg Res. 1995;59(6):705–11.CrossRefPubMed
9.
Phillips TJ, Gerstein AD, Lordan V. A randomized controlled trial of hydrocolloid dressing in the treatment of hypertrophic scars and keloids. Dermatol Surg. 1996;22(9):775–8.CrossRefPubMed
10.
Branagan M, Chenery DH, Nicholson S. Use of infrared attenuated total reflectance spectroscopy for the in vivo measurement of hydration level and silicone distribution in the stratum corneum following skin coverage by polymeric dressings. Skin Pharmacol Appl Skin Physiol. 2000;13(3–4):157–64.CrossRefPubMed
11.
Suetak T, Sasai S, Zhen YX, Tagami H. Effects of silicone gel sheet on the stratum corneum hydration. Br J Plast Surg. 2000;53(6):503–7.CrossRefPubMed
12.
Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast Surg. 2008;32(1):82–92.CrossRefPubMed
13.
Gilman TH. Silicone sheet for treatment and prevention of hypertrophic scar: a new proposal for the mechanism of efficacy. Wound Repair Regen. 2003;11(3):235–6.CrossRefPubMed
14.
Quinn KJ, Evans JH, Courtney JM, Gaylor JD, Reid WH. Non-pressure treatment of hypertrophic scars. Burns Incl Therm Inj. 1985;12(2):102–8.CrossRefPubMed
15.
Chike-Obi CJ, Cole PD, Brissett AE. Keloids: pathogenesis, clinical features, and management. Semin Plastic Surg. 2009;23(3):178–84.CrossRef
16.
Boyadjiev C, Popchristova E, Mazgalova J. Histomorphologic changes in keloids treated with Kenacort. J Trauma. 1995;38(2):299–302.CrossRefPubMed
17.
Manuskiatti WR, Fitzpatrick E. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol. 2002;138(9):1149–55.CrossRefPubMed
18.
Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110(2):560–71.CrossRefPubMed
19.
Draaijers LJ, Tempelman FR, Botman YA, et al. The patient and observer scar assessment scale: a reliable and feasible tool for scar evaluation. Plast Reconstr Surg. 2004;113(7):1960–5 (discussion 1966–7).CrossRefPubMed
20.
Verhaegen PD, van der Wal MD, Middelkoop E, van Zuijlen PP. Objective scar assessment tools: a clinimetric appraisal. Plast Reconstr Surg. 2011;127(4):1561–70.CrossRefPubMed
21.
van der Wal MBA, Tuinebreijer WE, Bloemen MCT, et al. Rasch analysis of the Patient and Observer Scar Assessment Scale (POSAS) in burn scars. Qual Life Res. 2012;21(1):13–23.CrossRefPubMed
22.
Katz BE. Silicone gel sheeting in scar therapy. Cutis. 1995;56(1):65–7.PubMed
23.
24.
Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plast Surg. 2007;31(5):468–92 (discussion 493–4).CrossRefPubMed
25.
Riaz Y, Cook HT, Wangoo A, Glenville B, Shaw RJ. Type 1 procollagen as a marker of severity of scarring after sternotomy: effects of topical corticosteroids. J Clin Pathol. 1994;47(10):892–9.CrossRefPubMedPubMedCentral
26.
Juckett G, Hartman-Adams H. Management of keloid and hypertrophic scars. Am Fam Physician. 2009;80(3):253–60.PubMed
27.
Tan E, Chua S, Lim J. Topical silicone gel sheet versus intralesional injections of triamcinolone acetonide in the treatment of keloid—a patient-controlled comparative clinical trial. J Dermatol Treat. 1999;10(4):251–4.CrossRef
28.
Li Tsang CW, Lau JC, Choi J, Chan CC, Jianan L. A prospective randomized clinical trial to investigate the effect of silicone gel sheeting (Cica-Care) on post-traumatic hypertrophic scar among Chinese population. Burns. 2006;32(6):678–83.CrossRefPubMed
29.
Li Tsang CWP, Zheng YP, Lau JCM. A randomized clinical trial to study the effect of silicone gel dressing and pressure therapy on posttraumatic hypertrophic scars. J Burn Care Res. 2010;31(3):448–57.CrossRefPubMed
30.
Saedi F, Saleh MA, Bhatti A, Juma A. Pain associated with intra lesional steroid injection for keloid/hypertrophic scars. Int J Surg. 2012;10(8):S67.
31.
Muneuchi G, Suzuki S, Onodera M, Ito O, Hata Y, Igawa HH. Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients. Scand J Plast Reconstr Surg Hand Surg. 2006;40(2):111–6.CrossRefPubMed
32.
Kelly AP. Medical and surgical therapies for keloids. Dermatol Therapy. 2004;17:212–8.CrossRef
33.
34.
Lynch WS. Local anesthetic in skin surgery. In: Epitein E, Epitein E Jr, editors. 6th edn. Philadelphia: WB Saunders Philadelphia; 1987. p. 25–35.
35.
Al Aradi IK, Alawadhi SA, Alkhawaja FA. Earlobe keloids: a pilot study of the efficacy of keloidectomy with core fillet flap and adjuvant intralesional corticosteroids. Dermatol Surg. 2013;39(10):1514–9.PubMed
36.
Shaffer, JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S63–97.
37.
Moustafa MF, Abdel-Fattah MA, Abdel-Fattah DC. Presumptive evidence of the effect of pregnancy estrogens on keloid growth. Case report. Plast Reconstr Surg. 1975;56(4):450–3.CrossRefPubMed
38.
Emad M, Omidvari S, Dastgheib L, Mortazavi A, Ghaem H. Surgical excision and immediate postoperative radiotherapy versus cryotherapy and intralesional steroids in the management of keloids: a prospective clinical trial. Med Princ Pract. 2010;19(5):402–5.CrossRefPubMed
39.
Jason E, Heidi W, Joel LC. Complications and their management. Dlm. (pnyt.). Ed. Illustrated manual of injectable fillers. Boca Raton: CRC Press; 2011. p. 139–66.
40.
Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 2013;6:295–316.PubMedPubMedCentral
41.
Curtis JA, Cormode E, Laski B, Toole J, Howard N. Endocrine complications of topical and intralesional corticosteroid therapy. Arch Dis Child. 1982;57(3):204–7.CrossRefPubMedPubMedCentral
Metadata
Title
A Randomized, Single-Blind Trial of Clobetasol Propionate 0.05% Cream Under Silicone Dressing Occlusion Versus Intra-Lesional Triamcinolone for Treatment of Keloid
Authors
Norazirah Md Nor
Rasimah Ismail
Adawiyah Jamil
Shamsul Azhar Shah
Farah Hani Imran
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 3/2017
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-016-0484-x

Other articles of this Issue 3/2017

Clinical Drug Investigation 3/2017 Go to the issue

Short Communication

Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study

Original Research Article

Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China

Original Research Article

Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan

Original Research Article

Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach

Short Communication

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers

Original Research Article

Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers